All In Biotech

Drug Trial Radar · NCT06488118

Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)

Lung Immune Challenge Study Controlled Exposure to Inhaled Resiquimod (R848) to Study Mechanisms of Inflammation

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 24, 2024

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Akhilesh JhaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Cambridge
First posted
Jul 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Respiratory viral infections can be a cause of significant illness, particularly in vulnerable individuals as seen in the COVID-19 pandemic. An underactive or overactive immune response can lead to ineffective resolution of inflammation after an infection, especially in people with airway diseases such as asthma. A better understanding of immune responses to infection that does not rely on cell or animal models is crucial to help develop better treatments for lung inflammation. An established method of studying inflammation in humans is through careful and controlled exposure (or "challenge") with a mimic of a virus to simulate an infection in a similar manner to that of a virus, but with the advantage of not causing an infection. The investigators have already developed a well-tolerated mimic of human viral infection using a sterile substance called Resiquimod (or R848). Since it does not contain living organisms there is no possibility of being infected. This has been used previously as a nasal spray to cause a mild short-lived inflammation that mimics a mild cold. This has been used safely in a range of people of different ages including those who have asthma. There are differences however in how the nose and lungs respond to viral infections. This is particularly true in those with airway diseases such as asthma, who have cells in the airways of their lungs that respond in a different way to inflammatory triggers (such as viruses). The current study aims to build on previous research by developing a new approach of studying inflammation in the lungs using a small volume of Resiquimod. This will be done by gently inhaling a fine mist through a mouthpiece into the lungs. Blood and phlegm samples would then be collected to assess inflammation and how well people tolerate the procedure.

Conditions

  • Innate Immunity
  • Mucosal Immunity
  • Asthma
  • Viral Infection

Interventions

  • R848Drug

    Inhaled R848 dose ranging from 0.1 to 100 μg/mL

  • SalineDrug

    Inhaled Saline control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Serum or Sputum CXCL10Time frame: 3 weeks from screening visit until 24 hours after inhaled R848 challenge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NIHR Cambridge Clinical Research Facility

    Cambridge, Cambridgeshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.